Estrogen increases methamphetamine (MA)-induced neurotoxicity within the impaired nigrostriatal dopaminergic (NSDA) system of ovariectomized female mice, as defined by enhanced striatal dopamine (DA) depletion. In this study we compared the effects of a lower dose of estradiol benzoate (EB, 1 µg) with related agents – tamoxifen (TMX, 12.5 µg), testosterone (5 µg) and dehydroepiandrosterone (DHEA, 3 mg) in this paradigm. In experiment 1, ovariectomized mice received an initial treatment with MA. At 1 week after MA, mice were treated with EB, TMX, testosterone, DHEA or oil vehicle and 24 h later a second MA treatment. Striatal DA and 3,4-dihydroxyphenylacetic acid (DOPAC) concentrations in the MA-treated groups were decreased compared to the non-MA-treated control. Neither EB nor any of the other agents tested showed enhanced neurodegenerative or neuroprotective effects against a second MA invasion. To verify that estrogen was capable of showing a neuroprotective effect under a condition of two administrations of MA, in experiment 2, EB was administered either once or twice prior to each of the two MA treatments. EB treatment prior to the first MA invasion or first and second MA protected the NSDA system against DA and DOPAC depletion. These results imply that a lower dose of EB, TMX, testosterone and DHEA cannot exert neurodegenerative or neuroprotective effects in the impaired NSDA model. However, EB administered prior to the introduction of neurotoxicity can protect the NSDA system. This study may provide an understanding of the variations in results on the effects of estrogen upon the NSDA neurodegenerative disorder, Parkinson’s disease.

Keywords:
Gonadal steroids, Dopamine, Striatum, Parkinson’s disease, Neuroprotection, Neurodegeneration
1.
Dluzen DE, McDermott JL: Neuroprotective role of estrogen upon methamphetamine and related neurotoxins within the nigrostriatal dopaminergic system. Ann NY Acad Sci 2000;914:112–126.
2.
Dluzen DE, McDermott JL: Estrogen, anti-estrogen, and gender: differences in methamphetamine neurotoxicity. Ann NY Acad Sci 2002;965:136–156.
3.
Dluzen DE, Anderson LI, Pilati CF: Methamphetamine-gonadal steroid hormonal interactions: effects upon acute toxicity and striatal dopamine concentrations. Neurotoxicol Teratol 2002;24:267–273.
4.
Yu L, Liao PC: Estrogen and progesterone distinctively modulate methamphetamine-induced dopamine and serotonin depletions in C57BL/6J mice. J Neural Transm 2000;107:1139–1147.
5.
Dluzen DE, McDermott JL, Liu B: Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice. Neurotoxicol Teratol 1996;18:603–606.
6.
Dluzen DE, McDermott JL, Liu B: Estrogen alters MPTP-induced neurotoxicity in female mice: effects on striatal dopamine concentrations and release. J Neurochem 1996;66:658–666.
7.
Grandbois M, Morissette M, Callier S, Di Paolo T: Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice. Neuroreport 2000;11:343–346.
8.
Dluzen D: Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine. Brain Res 1997;767:340–344.
9.
Gillies GE, Murray HE, Dexter D, McArthur S: Sex dimorphisms in the neuroprotective effects of estrogen in an animal model of Parkinson’s disease. Pharmacol Biochem Behav 2004;78:513–522.
10.
Gajjar TM, Anderson LI, Dluzen DE: Acute effects of estrogen upon methamphetamine induced neurotoxicity of the nigrostriatal dopaminergic system. J Neural Transm 2003;110:1215–1224.
11.
Gao X, Dluzen DE: Tamoxifen abolishes estrogen’s neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Neuroscience 2001;103:385–394.
12.
Gao X, Dluzen DE: The effect of testosterone upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Brain Res 2001;892:63–69.
13.
Liu B, Dluzen DE: Effect of estrogen upon methamphetamine-induced neurotoxicity within the impaired nigrostriatal dopaminergic system. Synapse 2006;60:354–361.
14.
Mickley KR, Dluzen DE: Dose-response effects of estrogen and tamoxifen upon methamphetamine-induced behavioral responses and neurotoxicity of the nigrostriatal dopaminergic system in female mice. Neuroendocrinology 2004;79:305–316.
15.
Lewis C, Dluzen DE: Effect of testosterone upon methamphetamine-induced neurotoxicity of striatal dopamine within male and female mice (abstract 345.4). 34th Annu Meet Soc Neurosci, San Diego, 2004.
16.
D’Astous M, Morissette M, Tanguay B, Callier S, Di Paolo T: Dehydroepiandrosterone (DHEA) such as 17beta-estradiol prevents MPTP-induced dopamine depletion in mice. Synapse 2003;47:10–14.
17.
Anderson LI, Leipheimer RE, Dluzen DE: Effects of neonatal and prepubertal hormonal manipulations upon estrogen neuroprotection of the nigrostriatal dopaminergic system within female and male mice. Neuroscience 2005;130:369–382.
18.
D’Astous M, Gajjar TM, Dluzen DE, DiPaolo T: Dopamine transporter as a marker of neuroprotection in methamphetamine-lesioned mice treated acutely with estradiol. Neuroendocrinology 2004;79:296–304.
19.
Yu L, Kuo Y, Cheng CG, Chen HH, Hsu CH: Ovarian hormones do not attenuate methamphetamine-induced dopaminergic neurotoxicity in mice gonadectomized at 4 weeks postpartum. Neuroendocrinology 2002;75:282–287.
20.
Euvrard C, Oberlander C, Boissier JR: Antidopaminergic effect of estrogens at the striatal level. J Pharmacol Exp Ther 1980;214:179–185.
21.
Xu K, Xu Y, Brown-Jermyn D, Chen JF, Ascherio A, Dluzen DE, Schwarzschild MA: Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. J Neurosci 2006;26:535–541.
22.
Murray HE, Pillai AV, McArthur SR, Razvi N, Datla KP, Dexter DT, Gillies GE: Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminergic pathway of adult rats: differential actions of estrogen in males and females. Neuroscience 2003;116:213–222.
23.
Dluzen DE, McDermott JL, Anderson LI: Tamoxifen diminishes methamphetamine-induced striatal dopamine depletion in intact female and male mice. J Neuroendocrinol 2001;13:618–624.
24.
Obata T, Kubota S: Protective effect of tamoxifen on 1-methyl-4-phenylpyridine-induced hydroxyl radical generation in the rat striatum. Neurosci Lett 2001;308:87–90.
25.
Aragno M, Tamagno E, Gatto V, Brignardello E, Parola S, Danni O, Boccuzzi G: Dehydroepiandrosterone protects tissues of streptozotocin-treated rats against oxidative stress. Free Radic Biol Med 1999;26:1467–1474.
26.
Boccuzzi G, Aragno M, Seccia M, Brignardello E, Tamagno E, Albano E, Danni O, Bellomo G: Protective effect of dehydroepiandrosterone against copper-induced lipid peroxidation in the rat. Free Radic Biol Med 1997;22:1289–1294.
27.
Tomas-Camardiel M, Sanchez-Hidalgo MC, Sanchez del Pino MJ, Navarro A, Machado A, Cano J: Comparative study of the neuroprotective effect of dehydroepiandrosterone and 17beta-estradiol against 1-methyl-4-phenylpyridium toxicity on rat striatum. Neuroscience 2002;109:569–584.
28.
Marx CE, Jarskog LF, Lauder JM, Gilmore JH, Lieberman JA, Morrow AL: Neurosteroid modulation of embryonic neuronal survival in vitro following anoxia. Brain Res 2000;871:104–112.
29.
Ramirez AD, Liu X, Menniti FS: Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice. Neuroendocrinology 2003;77:223–231.
30.
Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE: Caffeine, postmenopausal estrogen, and risk of Parkinson’s disease. Neurology 2003;60:790–795.
31.
Benedetti MD, Maraganore DM, Bower JH, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA: Hysterectomy, menopause, and estrogen use preceding Parkinson’s disease: an exploratory case-control study. Mov Disord 2001;16:830–837.
32.
Blanchet PJ, Fang J, Hyland K, Arnold LA, Mouradian MM, Chase TN: Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study. Neurology 1999;53:91–95.
33.
Currie LJ, Harrison MB, Trugman JM, Bennett JP, Wooten GF: Postmenopausal estrogen use affects risk for Parkinson disease. Arch Neurol 2004;61:886–888.
34.
Popat RA, Van Den Eeden SK, Tanner CM, McGuire V, Bernstein AL, Bloch DA, Leimpeter A, Nelson LM: Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. Neurology 2005;65:383–390.
35.
Saunders-Pullman R, Gordon-Elliott J, Parides M, Fahn S, Saunders HR, Bressman S: The effect of estrogen replacement on early Parkinson’s disease. Neurology 1999;52:1417–1421.
36.
Tsang KL, Ho SL, Lo SK: Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology 2000;54:2292–2298.
37.
Bedard P, Langelier P, Villeneuve A: Oestrogens and extrapyramidal system. Lancet 1977;2:1367–1368.
38.
Marder K, Tang MX, Alfaro B, Mejia H, Cote L, Jacobs D, Stern Y, Sano M, Mayeux R: Postmenopausal estrogen use and Parkinson’s disease with and without dementia. Neurology 1998;50:1141–1143.
39.
Strijks E, Kremer JA, Horstink MW: Effects of female sex steroids on Parkinson’s disease in postmenopausal women. Clin Neuropharmacol 1999;22:93–97.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.